At what stage in the development of an R&D project should patient organisations qualify as partners?

BioFIT is the meeting point in Europe for tech transfer and for sourcing early-stage innovations stemming from public research institutions, academic spin-offs and emerging biotech companies. In December 2021 Chase Partners moderated a panel discussion on the optimal time for involvement in working with patient groups in early stage R and D.

The four member panel comprised of representatives from Big Pharma, Small Life Bioscience, Patient Groups and Investment Funds . The session was entitled At what stage in the development of an R&D project should patient organisations qualify as partners?

Biofit Report Chase Partners.pdf

Download PDF • 1.37MB